Novo Nordisk A/S
Copenhagen : NOVO B

May 31, 2013 05:02 ET

Novo Nordisk A/S: Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes

BAGSVAERD, DENMARK--(Marketwired - May 31, 2013) -

Novo Nordisk today announced the submission to the European Medicines Agency of the marketing authorisation application for the approval of IDegLira, the combination product of insulin degludec (Tresiba®), the once-daily new-generation basal insulin analogue, with an ultra-long duration of action, and liraglutide (Victoza®), the once-daily human GLP-1 analogue. IDegLira has been developed for the treatment of people with type 2 diabetes.

Company announcement No 41 / 2013:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Contact Information